September 2006
Worldwide Biotech;Sep2006, Vol. 18 Issue 9, p2
Trade Publication
The article presents an update on the preparations of biopharmaceutical company Liponex Inc. for Phase I/II clinical trial of its lead compound CRD5 for the treatment of dyslipidemia and heart disease. The bulk active pharmaceutical ingredient from contract manufacturer has been received by the company and quality testing and analysis has also been completed. The coverage of the trial is detailed.


Related Articles

  • LIPONEX GRANTED U.S. PATENT ALLOWANCE FOR CRD5.  // Worldwide Biotech;Dec2004, Vol. 16 Issue 12, p2 

    Reports on the U.S. patent allowance granted to the CRD5 drug developed by Ottawa, Ontario-based Liponex Inc. Therapeutic uses for the drug; Results of the clinical trials to test the safety of the drug; Discovery of the technology behind the drug.

  • He Who Pays the Piper Calls the Tune: The Role of the Industry Sponsor in Acute Stroke Trials. Bozik, Michael // European Neurology;2003, Vol. 49 Issue 2, p128 

    Ischemic stroke remains a complex neurobiological and clinical disease, and stroke drug development remains time consuming and costly. In addressing these challenges, the pharmaceutical industry has a principal responsibility to ensure that the acute stroke trials it sponsors are ethically...

  • When the MAGIC stops: magnesium in acute coronary syndromes -- a lesson in medical humility. Patrick, Shannon; Herbert, Mel // CJEM: Canadian Journal of Emergency Medicine;Mar2004, Vol. 6 Issue 2, p123 

    There has been much debate as to whether magnesium, a well-tolerated, readily available and cheap therapy, should be used to treat patients with suspected myocardial infarction. Despite promising results from animal studies and small clinical trials Conducted in the 1980s, two large recent...

  • Trial Scorecards.  // Cardiology Today;Apr2009, Vol. 12 Issue 4, p8 

    The article presents summaries of the latest outcomes of various clinical trials in cardiology.

  • Johnson & Johnson: Natrecor safety ripe for reexamination.  // PharmaWatch: Monthly Review;Jun2005, Vol. 4 Issue 6, p15 

    The article reports on the study that Nesiritide may have an increased risk of death after treatment for acutely decompensated heart failure. Although Johnson & Johnson, which manufactures nesiritide, has rightly pointed out that further clinical trials will done about the drug, the Journal of...

  • The impact of a reduced dose of dexamethasone on glucose control after coronary artery bypass surgery. Vogelzang, Mathijs; Hoekstra, Miriam; Drost, José T.; Janse, Marcel; van der Horst, Iwan C.C.; Boonstra, Piet W.; Zijlstra, Felix; Loef, Bert G.; Nijsten, Maarten W.N. // Cardiovascular Diabetology;2007, Vol. 6, p39 

    Background: Intensive insulin therapy to maintain normoglycemia after cardiac surgery reduces morbidity and mortality. We investigated the magnitude and duration of hyperglycemia caused by dexamethasone administered after cardiopulmonary bypass. Methods: A single-center before-after cohort study...

  • Grant Budgeting and Negotiating in India and China. Jankosky, Jena; Ying Jiang; Farwell, Ted // Applied Clinical Trials;Nov2007, Vol. 16 Issue 11, p56 

    The article discusses the effects of a rapidly developing market for clinical trials, namely in China and India, for researchers with less understanding and experience with cultural issues. China and India are burgeoning regions for the pharmaceutical industry and represent what some have called...

  • Effects of Antibiotic Therapy on Outcomes of Patients With Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials. Andraws, Richard; Berger, Jeffrey S.; Brown, David L. // JAMA: Journal of the American Medical Association;6/1/2005, Vol. 293 Issue 21, p2641 

    Context Although Chlamydia pneumoniae infection has been associated with the initiation and progression of atherosclerosis, results of clinical trials investigating antichlamydial antibiotics as adjuncts to standard therapy in patients with coronary artery disease (CAD) have been inconsistent....

  • Update on the collaborative interventions for circulation and depression (COINCIDE) trial: changes to planned methodology of a cluster randomized controlled trial of collaborative care for depression in people with diabetes and/or coronary heart disease. Coventry, Peter A.; Lovell, Karina; Dickens, Chris; Bower, Peter; Chew-Graham, Carolyn; Cherrington, Andrea; Garrett, Charlotte; Gibbons, Chris J.; Baguley, Clare; Roughley, Kate; Adeyemi, Isabel; Keyworth, Chris; Waheed, Waquas; Hann, Mark; Davies, Linda; Jeeva, Farheen; Roberts, Chris; Knowles, Sarah; Gask, Linda // Trials;2013, Vol. 14 Issue 1, p2 

    Background: The COINCIDE trial aims to evaluate the effectiveness and cost-effectiveness of a collaborative care intervention for depression in people with diabetes and/or coronary heart disease attending English general practices. Design: This update details changes to the cluster and patient...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics